Cover Image
市場調查報告書

呼吸疾病治療藥的全球市場

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

出版商 GBI Research 商品編碼 369232
出版日期 內容資訊 英文 202 Pages
訂單完成後即時交付
價格
Back to Top
呼吸疾病治療藥的全球市場 Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
出版日期: 2016年08月01日 內容資訊: 英文 202 Pages
簡介

到目前的呼吸疾病治療方法,大部分都非解除病因,而是緩和疾病的症狀的小分子療法。可是,這10年來治療方法大幅進化,開發出許多新治療藥和標靶治療。2015年11月時,全部有908種產品,作為呼吸疾病治療藥進行臨床實驗。

本報告提供全球呼吸疾病治療藥的市場現況與未來展望相關分析,主要的呼吸疾病概要,及現在已上市的產品的概要,現在臨床實驗中的開發中產品一覽和臨床實驗的進展,今後的市場成長、技術開發 (臨床實驗進展)的預測,主要企業的概要與競爭策略,今後的產業重組預測等相關調查與考察。

第1章 目錄

第2章 簡介

  • 醫療領域:概論
  • 流行病學
    • 氣喘
    • 慢性閉塞性肺纖維化 (COPD)
    • 突發性肺纖維化 (IPF)
    • 囊狀纖維化症 (CF)
  • 病理生理學
  • 症狀
  • 診斷方法
  • 疾病的嚴重度和預後
  • 治療方法

第3章 主要已上市產品

  • 概要
  • Advair - GSK
  • Spiriva - Boehringer Ingelheim, Pfizer
  • Symbicort - AstraZeneca/Astellas
  • Singulair (montelukast) - Merck & Co.
  • Flixotide/Flovent - GSK
  • Ventolin - GSK
  • Kalydeco - Vertex
  • Pulmozyme - Roche
  • Esbriet - Roche
  • TOBI - Novartis
  • 結論

第4章 開發中產品的市場環境分析

  • 概要
  • 開發中產品的開發環境
  • 開發平台上的分子標的
  • 臨床實驗的進展
    • 失敗率:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 臨床實驗的有效期:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 臨床實驗的規模:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 整體臨床實驗計劃數:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 結論

第5章 多方案市場分析 (到2022年)

  • 市場規模:概要
  • 學名藥的普及率
  • 各分子標的收益額預測
    • G蛋白偶聯受體
    • 免疫/發炎媒介物質
    • 轉錄因子
    • 信號傳達
    • CFTR (囊狀纖維化症薄膜傳導控制因素) 調整劑
  • 主要的開發中產品的評估
    • Dupilumab - Regeneron Pharmaceuticals/Sanofi
    • Benralizumab - AstraZeneca/Medimmune
    • Lebrikizumab - Roche/Genentech
    • PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
    • Tralokinumab - AstraZeneca
    • Batefenterol - GSK/Theravance
    • 結論

第6章 企業的分析與定位

  • 各企業的收益額、市場佔有率分析
    • GlaxoSmithKline
    • Vertex
    • AstraZeneca
    • Roche
    • Novartis
    • Boehringer Ingelheim
  • 企業環境
  • 已上市/開發中產品的組合分析

第7章 產業重組的策略

  • 授權合約交易
    • 各地區、各年度的交易趨勢/金額
    • 各臨床實驗階段的交易趨勢/金額
    • 各分子類型、各分子標的交易趨勢
    • 交易額1億美元以上的交易的一覽
  • 共同開發交易

第8章 附錄

  • 參考文獻
  • 全開發中產品:各階段 (相位)
  • 簡稱一覽
  • 分析方法
  • 聯絡處資訊
  • 免責聲明

圖表一覽

目錄
Product Code: GBIHC409MR

Executive Summary

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active in development for respiratory disorders.

Scope

The respiratory disorders market is characterized by entrenched, commercially successful therapies.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?
  • What are the future prospects for the leading brands?

The pipeline contains a range of molecule types and molecular targets, with a growing presence of targeted therapies.

  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?

Respiratory disorders clinical trials have an overall attrition rate of 89.1%.

  • What are the failure rates at individual phases of clinical development?
  • How do the key respiratory disorders compare in terms of clinical trial failure rate?

The respiratory disorders market is forecast to rise from a value of $28.1 billion in 2015 to $46.6 billion in 2022, at a CAGR of 7.5%.

  • How much of a role will pipeline product approvals play in market growth?
  • Are the large number of recently approved products expected to drive market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
  • Which products face generic competition?

Big pharma holds a notable presence in the market.

  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • Which company will hold the largest market share in 2022?
  • How dependent are the key companies on this disease cluster for revenue?
  • Which companies rely heavily on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment landscape in respiratory disorders.
  • Assess the current treatment landscape, with product profiles on prominent marketed therapies, including revenue forecasts.
  • Analyze the respiratory disorders pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory disorder products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the respiratory disorder deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Epidemiology
    • 2.2.1. Asthma
    • 2.2.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.2.3. Idiopathic Pulmonary Fibrosis
    • 2.2.4. Cystic Fibrosis
  • 2.3. Pathophysiology
    • 2.3.1. Asthma
    • 2.3.2. Chronic Obstructive Pulmonary Disease
    • 2.3.3. Idiopathic Pulmonary Fibrosis
    • 2.3.4. Cystic Fibrosis
  • 2.4. Symptoms
  • 2.5. Diagnosis
    • 2.5.1. Asthma
    • 2.5.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.5.3. Idiopathic Pulmonary Fibrosis
    • 2.5.4. Cystic Fibrosis
  • 2.6. Disease Severity and Prognosis
    • 2.6.1. Asthma
    • 2.6.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.6.3. Idiopathic Pulmonary Fibrosis
    • 2.6.4. Cystic Fibrosis
  • 2.7. Treatment
    • 2.7.1. Asthma
    • 2.7.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.7.3. Idiopathic Pulmonary Fibrosis
    • 2.7.4. Cystic Fibrosis

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Advair - GSK
  • 3.3. Spiriva - Boehringer Ingelheim, Pfizer
  • 3.4. Symbicort - AstraZeneca/Astellas
  • 3.5. Singulair (montelukast) - Merck & Co.
  • 3.6. Flixotide/Flovent - GSK
  • 3.7. Ventolin - GSK
  • 3.8. Kalydeco - Vertex
  • 3.9. Pulmozyme - Roche
  • 3.10. Esbriet - Roche
  • 3.11. TOBI - Novartis
  • 3.12. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion

5. Multi-scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. G-Protein Coupled Receptors
    • 5.3.2. Immune/Inflammatory Mediators
    • 5.3.3. Transcription Factors
    • 5.3.4. Signal Transduction
    • 5.3.5. CFTR Modulator
  • 5.4. Assessment of Key Pipeline Products
    • 5.4.1. Dupilumab - Regeneron Pharmaceuticals/Sanofi
    • 5.4.2. Benralizumab - AstraZeneca/Medimmune
    • 5.4.3. Lebrikizumab - Roche/Genentech
    • 5.4.4. PT010(Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
    • 5.4.5. Tralokinumab - AstraZeneca
    • 5.4.6. Batefenterol - GSK/Theravance
    • 5.4.7. Conclusion

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. GlaxoSmithKline
    • 6.1.2. Vertex
    • 6.1.3. AstraZeneca
    • 6.1.4. Roche
    • 6.1.5. Novartis
    • 6.1.6. Boehringer Ingelheim
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deal by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type and Molecular Target
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. All Pipeline Drugs by Phase
    • 8.2.1. Discovery
    • 8.2.2. Preclinical
    • 8.2.3. IND/CTA filed/Phase 0
    • 8.2.4. Phase I
    • 8.2.5. Phase II
    • 8.2.6. Phase III
    • 8.2.7. Pre-registration
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2016
  • Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
  • Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
  • Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults
  • Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016
  • Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016
  • Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016
  • Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016
  • Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016
  • Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016
  • Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2016
  • Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Spiriva, 2016
  • Table 13: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2016
  • Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2016
  • Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Flixotide, 2016
  • Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2016
  • Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2016
  • Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmozyme, 2016
  • Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2016
  • Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for TOBI, 2016
  • Table 21: Respiratory DIsorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
  • Table 22: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016
  • Table 23: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 24: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Table 25: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2016
  • Table 26: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2016
  • Table 27: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA filed/Phase 0, 2016
  • Table 28: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2016
  • Table 29: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2016
  • Table 30: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2016
  • Table 31: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016

List of Figures

  • Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2015-2023
  • Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2015-2023
  • Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2015-2023
  • Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2015-2023
  • Figure 5: Respiratory Disorders Therapeutics Market, Clinical Courses of IPF
  • Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF
  • Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2016
  • Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Advair ($bn), 2006-2022
  • Figure 9: Respiratory Disorders Therapeutic Market, Global, Annual Revenues for Spiriva ($bn), 2006-2022
  • Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Symbicort ($bn), 2006-2022
  • Figure 11: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Singulair ($bn), 2006-2022
  • Figure 12: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Flixotide ($m), 2006-2022
  • Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Ventolin ($m), 2006-2022
  • Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Kalydeco ($bn), 2012-2022
  • Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmozyme ($m), 2006-2022
  • Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($bn), 2011-2022
  • Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for TOBI ($m), 2006-2020
  • Figure 18: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 19: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 20: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2016
  • Figure 21: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2016
  • Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2016
  • Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2016
  • Figure 24: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 25: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 26: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 29 Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006-2016
  • Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2016
  • Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2016
  • Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2016
  • Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006-2016
  • Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2016
  • Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2016
  • Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2016
  • Figure 40: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2015-2022
  • Figure 41: Respiratory DIsorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Figure 42: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
  • Figure 43: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2015-2022
  • Figure 44: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2015-2022
  • Figure 45: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2015-2022
  • Figure 46: Respiratory DIsorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2015-2022
  • Figure 47: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2015-2022
  • Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupilumab ($bn), 2017-2022
  • Figure 49: Respiratory DIsorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2018-2022
  • Figure 50: Respiratory Disorders Therapeutics Market, Global, Revenue for Lebrizikumab ($m), 2017-2022
  • Figure 51: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017-2022
  • Figure 52: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017-2022
  • Figure 53: Respiratory Disorders Therapeutics Market, Global, Revenue for Batefenterol ($m), 2019-2022
  • Figure 54: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2015-2022
  • Figure 55: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 56: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 57: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2015-2022
  • Figure 58: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2015-2022
  • Figure 59: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($m), 2015-2022
  • Figure 60: Respiratory DIsorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($m), 2015-2022
  • Figure 61: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($m), 2015-2022
  • Figure 62: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2015-2022
  • Figure 63: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($m), 2015-2022
  • Figure 64: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2016
  • Figure 65: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2016
  • Figure 66: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2015-2022
  • Figure 67: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, Top Six Companies ($bn), 2015-2022
  • Figure 68: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
  • Figure 69: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006-2016
  • Figure 70: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006-2016
  • Figure 71: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
  • Figure 72: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
  • Figure 73: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
  • Figure 74: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006-2016
  • Figure 75: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016
Back to Top